NasdaqGS:TSLA
NasdaqGS:TSLAAuto

This Week In Electric Vehicles - Riding The Wave Of EV Market Expansion

Recent developments in the electric vehicles (EV) sector underscore significant growth opportunities, driven by advancements in battery electric vehicles (BEVs) and lithium-iron-phosphate (LFP) batteries, bolstered by government support and expanding EV infrastructure. While the Asia Pacific region currently dominates the market, regions such as the Middle East and Africa are experiencing rapid growth. Challenges remain, including the high upfront costs of EVs and limited recycling facilities...
NYSE:KBH
NYSE:KBHConsumer Durables

What KB Home (KBH)'s New $1.2 Billion Credit Agreement Means for Shareholders

On November 12, 2025, KB Home entered into a new revolving credit agreement with Bank of America providing up to US$1.2 billion in commitments, replacing its prior facility, and also extended the maturity of its US$360 million senior unsecured term loan to November 12, 2029. These debt financing activities enhance KB Home's liquidity and financial flexibility, positioning the company to fund operations or expansion as market conditions evolve. We’ll assess how this substantial increase in...
NYSE:MODG
NYSE:MODGLeisure

Is Topgolf Callaway Brands (MODG) Still Undervalued After Recent Rally? A Fresh Look at Valuation

Topgolf Callaway Brands (MODG) has caught the attention of investors this month with its stock rising about 13% over the past month. Recent trading activity reflects renewed interest, as the company continues to navigate the consumer durables sector. See our latest analysis for Topgolf Callaway Brands. Momentum has been building for Topgolf Callaway Brands, as shown by its 25.95% total shareholder return over the past year. This comes after a long stretch of underperformance. Recent share...
NYSE:GME
NYSE:GMESpecialty Retail

The Bull Case For GameStop (GME) Could Change Following Strong Earnings and Continued Online Expansion

GameStop recently reported improved financial results, with higher revenue and significantly better net income compared to the previous year, reflecting the ongoing transformation under CEO Ryan Cohen. The company’s expanded online presence and moves into collectibles and cryptocurrency have drawn interest, but investors remain watchful about the durability of this turnaround. Given these changes and the focus on online expansion, we’ll examine how GameStop’s evolving strategy shapes its...
NYSE:CRBG
NYSE:CRBGDiversified Financial

Corebridge Financial (CRBG): Exploring Valuation After Recent Share Price Decline

Corebridge Financial (CRBG) shares have slipped over the past month, dropping about 11%. Investors are likely watching to see if the company’s fundamentals can spark renewed interest after this stretch of softer trading. See our latest analysis for Corebridge Financial. Shares have trended down lately, with a 1-month share price return of -10.6% and year-to-date performance now just below even. Despite recent weakness, Corebridge’s 3-year total shareholder return stands out at 65.5%, which...
NYSE:ENS
NYSE:ENSElectrical

Is EnerSys' (ENS) Aggressive Buyback Pace a Hint at Undervaluation or a Shift in Strategy?

Earlier this month, EnerSys reported second quarter revenue of US$951.29 million and announced the completion of two share repurchase tranches, buying back nearly 1.6 million shares for a combined US$104.25 million, while also affirming its next quarterly dividend of US$0.2625 per share and providing net sales guidance of US$920 million to US$960 million for the third quarter of fiscal 2026. EnerSys leadership confirmed M&A remains a core focus, with available capital reserved for...
NYSE:FMC
NYSE:FMCChemicals

FMC (FMC): Taking Stock of Valuation After a 70% Slide in 2024

FMC (FMC) has faced a challenging stretch this year, with shares down over 70% since January and trailing further over the past month. That kind of performance is raising questions about where things might go from here, especially as investors watch for signs of a turnaround. See our latest analysis for FMC. FMC’s 1-day share price return of -1.45% isn’t the full story. The company’s -72% year-to-date slide and -74% total return over the past year put the current stock price under the...
NasdaqCM:XPEL
NasdaqCM:XPELAuto Components

XPEL (XPEL): Assessing Valuation Following Q3 Results, New Product Launch, and Expansion Plans

XPEL (XPEL) just released third quarter earnings, reporting higher revenue but a slight decrease in net income compared to last year. The company also unveiled its new COLOR Paint Protection Film at the SEMA Show and shared plans for expansion. See our latest analysis for XPEL. Despite some recent volatility, XPEL’s share price has surged nearly 20% over the past month and rallied over 12% in just the past week. The market has responded to strong revenue growth, ambitious expansion plans, and...
NasdaqGS:WDAY
NasdaqGS:WDAYSoftware

Is Now the Right Time to Reassess Workday After Recent AI Partnership News?

Ever wondered whether Workday stock is truly a bargain, or if it's just treading water amid the tech sector buzz? You're not alone. Plenty of investors are asking the same question right now. Recently, Workday's share price has dipped by 0.4% over the last week and fallen 5.8% in the past month, continuing a downward trend of -11.3% year-to-date and -17.7% over the past year, but still holding onto a three-year gain of 50.2%. Workday has been in the headlines lately due to new partnerships...
NasdaqCM:CLDX
NasdaqCM:CLDXBiotechs

What Celldex Therapeutics (CLDX)'s Strong Barzolvolimab Data and Commercial Focus Mean for Shareholders

Celldex Therapeutics recently reported robust positive Phase 2 data for barzolvolimab in chronic spontaneous urticaria, cold urticaria, and symptomatic dermatographism, highlighting rapid and sustained disease control and a favorable safety profile even after treatment ended. The company also appointed Teri Lawver, an experienced leader in biologic launches and immunology, as Chief Commercial Officer, reflecting a sharpened focus on commercial strategy as late-stage trials advance. We'll...